- Home
- WRBY vs MYGN Comparison
WRBY vs MYGN Comparison
Compare WRBY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- MYGN
- Stock Information
- Founded
- WRBY 2010
- MYGN 1991
- Country
- WRBY United States
- MYGN United States
- Employees
- WRBY N/A
- MYGN N/A
- Industry
- WRBY Ophthalmic Goods
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WRBY Health Care
- MYGN Health Care
- Exchange
- WRBY Nasdaq
- MYGN Nasdaq
- Market Cap
- WRBY 2.1B
- MYGN 744.7M
- IPO Year
- WRBY 2021
- MYGN 1995
- Fundamental
- Price
- WRBY $22.24
- MYGN $5.60
- Analyst Decision
- WRBY Buy
- MYGN Hold
- Analyst Count
- WRBY 15
- MYGN 15
- Target Price
- WRBY $23.33
- MYGN $15.14
- AVG Volume (30 Days)
- WRBY 1.9M
- MYGN 1.6M
- Earning Date
- WRBY 08-07-2025
- MYGN 08-05-2025
- Dividend Yield
- WRBY N/A
- MYGN N/A
- EPS Growth
- WRBY N/A
- MYGN N/A
- EPS
- WRBY N/A
- MYGN N/A
- Revenue
- WRBY $795,094,000.00
- MYGN $831,300,000.00
- Revenue This Year
- WRBY $16.13
- MYGN N/A
- Revenue Next Year
- WRBY $13.87
- MYGN $6.68
- P/E Ratio
- WRBY N/A
- MYGN N/A
- Revenue Growth
- WRBY 13.94
- MYGN 7.38
- 52 Week Low
- WRBY $12.46
- MYGN $3.81
- 52 Week High
- WRBY $28.68
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- WRBY 60.97
- MYGN 59.81
- Support Level
- WRBY $21.48
- MYGN $4.90
- Resistance Level
- WRBY $22.52
- MYGN $5.74
- Average True Range (ATR)
- WRBY 0.76
- MYGN 0.27
- MACD
- WRBY -0.13
- MYGN 0.10
- Stochastic Oscillator
- WRBY 83.48
- MYGN 85.71
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.